• Explore /
  • Poster
  • / Updated survival, toxicity, and biomarkers of nivolumab with/without peptide vaccine in patients naive to, or progressed on, ipilimumab (IPI).

Updated survival, toxicity, and biomarkers of nivolumab with/without peptide vaccine in patients naive to, or progressed on, ipilimumab (IPI).

Abstract Poster

Authors

null

Jeffrey S. Weber

Moffitt Cancer Center, Comprehensive Melanoma Research Center, Tampa, FL

Jeffrey S. Weber , Ragini Reiney Kudchadkar , Geoffrey Thomas Gibney , Bin Yu , PingYan Cheng , Alberto J Martinez , Jodi Kroeger , Donna Gallenstein , Allison Richards , Eric Welsh , Xiuhua Zhao , Xiaotao Qu , Ann Chen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Developmental Therapeutics - Immunotherapy

Track

Developmental Therapeutics

Sub Track

Biomarkers and Correlative Studies from Immunotherapy Trials

Clinical Trial Registration Number

NCT01176461

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 3009)

DOI

10.1200/jco.2014.32.15_suppl.3009

Abstract #

3009

Poster Bd #

1

Abstract Disclosures

Similar Posters

First Author: Jeffrey S. Weber

First Author: Eileen M. O'Reilly

Poster

2024 ASCO Genitourinary Cancers Symposium

Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.

Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.

First Author: Michelle Hsu

First Author: Robert L. Ferris